e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Pathobiology of experimental pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late-breaking abstract: Intracellular mechanisms behind the effect of C-reactive protein on proximal vascular cells of CTEPH patients
M. Wynants, R. Quarck, B. Meyns, M. Delcroix (Leuven, Belgium)
Source:
Annual Congress 2011 - Pathobiology of experimental pulmonary hypertension
Session:
Pathobiology of experimental pulmonary hypertension
Session type:
Oral Presentation
Number:
3430
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Wynants, R. Quarck, B. Meyns, M. Delcroix (Leuven, Belgium). Late-breaking abstract: Intracellular mechanisms behind the effect of C-reactive protein on proximal vascular cells of CTEPH patients. Eur Respir J 2011; 38: Suppl. 55, 3430
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension},
Source: Eur Respir J 2012; 40: 886-894
Year: 2012
The systemic face of airway diseases: the role of C-reactive protein
Source: Eur Respir J 2006; 27: 877-879
Year: 2006
Vascular wall remodeling in patients with chronic thromboembolic pulmonary hypertension: a role for C-reactive protein
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
Differences in cellular expression of C-reactive protein and serum amyloid A in lung tissue in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2012 - Inflammatory mechanisms in COPD
Year: 2012
Levels of serum amyloid A (SAA) and C-reactive protein (CRP) in stable COPD patients and its relationship with disease severity.
Source: International Congress 2017 – COPD biomarkers
Year: 2017
C-reactive protein (CRP) as a risk marker in COPD patients with ischaemic heart disease
Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD
Year: 2008
Serum C-reactive protein concentrations in patients with sarcoidosis: can be taken this simple test as an activation marker in sarcoidosis?
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004
Is there a relationship between severity of COPD and C-reactive protein (CRP) levels?
Source: Eur Respir J 2006; 28: Suppl. 50, 37s
Year: 2006
C-reactive protein in pulmonary tuberculosis-correlation with extent and severity of the disease
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients
Source: Eur Respir J 2006; 27: 902-907
Year: 2006
The comparison of diagnostic relevance of protein C, C-reactive protein and endothelin-1 for prediction of lung vessel thrombosis in patients with community-acquired pneumonia
Source: International Congress 2019 – Complex respiratory infections in clinical practice
Year: 2019
Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?
Source: Eur Respir J 2008; 32: 1451-1457
Year: 2008
The relationship between level of C-reactive protein in blood serum and clinical manifestations of the disease in patients with pulmonary tuberculosis
Source: Annual Congress 2010 - Tuberculosis: metabolic insights
Year: 2010
Independent contribution of C-reactive protein and oxygen status of arterial blood to tissue hypoxia in stable COPD patients
Source: Eur Respir J 2007; 30: Suppl. 51, 771s
Year: 2007
Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
LSC - 2021 - The relationship between the level of C-reactive protein and the general cardiovascular risk in patients with COPD and hypertension
Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD
Year: 2021
Vascular remodeling in chronic thromboembolic pulmonary hypertension: Involvement of dedifferentiated smooth muscle cells and C-reactive protein
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010
Elevated factor FVIII:C levels in patients with pulmonary hypertension: a marked of endothelial dysfunction?
Source: Eur Respir J 2003; 22: Suppl. 45, 584s
Year: 2003
C-reactive protein and serum amyloid A overexpression in lung tissues of chronic obstructive pulmonary disease patients
Source: Annual Congress 2012 - Inflammatory mechanisms in COPD
Year: 2012
High-sensitive C-reactive protein is associated with reduced lung function in young adults
Source: Eur Respir J 2009; 33: 382-388
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept